← Back to Search

Monoclonal Antibodies

JNJ-77242113 for Plaque Psoriasis (FRONTIER 2 Trial)

Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 40
Awards & highlights

FRONTIER 2 Trial Summary

This trial will study the long-term effects of JNJ-77242113 on moderate-to-severe plaque psoriasis.

Eligible Conditions
  • Plaque Psoriasis

FRONTIER 2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 40
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 40 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 36
Secondary outcome measures
Change From Baseline in PASI Total Score at Week 36
Change from Baseline in PSSD Signs Score at Week 36
Change from Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 36
+7 more

FRONTIER 2 Trial Design

6Treatment groups
Experimental Treatment
Group I: Group 6: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group II: Group 5: JNJ-77242113 Dose 3 BIDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
Group III: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
Group IV: Group 3: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group V: Group 2: JNJ-77242113 Dose 2 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
Group VI: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-77242113
2022
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
977 Previous Clinical Trials
6,384,473 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
746 Previous Clinical Trials
3,960,051 Total Patients Enrolled

Media Library

Plaque Psoriasis Research Study Groups: Group 1: JNJ-77242113 Dose 1 Once Daily (QD), Group 2: JNJ-77242113 Dose 2 QD, Group 3: JNJ-77242113 Dose 3 QD, Group 4: JNJ-77242113 Dose 1 Twice Daily (BID), Group 5: JNJ-77242113 Dose 3 BID, Group 6: JNJ-77242113 Dose 3 QD
Plaque Psoriasis Clinical Trial 2023: JNJ-77242113 Highlights & Side Effects. Trial Name: NCT05364554 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential risks associated with taking JNJ-77242113?

"JNJ-77242113's safety was rated a 2 because there is some evidence attesting to its safety, but no data yet confirming its efficacy in Phase 2 of the trial."

Answered by AI

Are people currently being signed up to participate in this experiment?

"That is correct. The information available on clinicaltrials.gov confirms that this study, which was first advertised on 6/10/2022, is still recruiting patients. In total, they are hoping to enroll 228 individuals at 20 different research sites."

Answered by AI

Are there any research facilities in North America testing this new treatment?

"To lessen the burden of travel, patients are encouraged to select a clinical trial site from the 20 locations that is nearest to them. Some of these 20 sites include cities such as Waterloo, Hamilton and Montreal."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
Pennsylvania
California
Other
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
What site did they apply to?
Pacific Skin Institute
Indiana Clinical Trial Center
University of Pittsburgh Department of Dermatology
How many prior treatments have patients received?
1
3+

What questions have other patients asked about this trial?

How much is the pay? How long does it take? How long will screening tests take?
PatientReceived 2+ prior treatments

Why did patients apply to this trial?

Clear my psoriasis. I've tried other drugs and I'm hoping this will work better.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Email
Phone Call
Most responsive sites:
  1. Indiana Clinical Trial Center: < 48 hours
  2. University of Pittsburgh Department of Dermatology: < 48 hours
Recent research and studies
clinicaltrials.govStudy
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
2022. "A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05364554.
~78 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top